Hologic completes US$310m acquisition

The US medtech company Hologic has acquired Endomagnetics, a UK-based developer of breast cancer surgery technologies, for approximately US$310m.

The previously announced transaction adds Endomag’s wireless breast surgery localisation and lymphatic tracing solutions to Hologic’s breast surgery portfolio.

The addition is hoped to provide breast surgeons and radiologists with an expanded range of options and enhanced user experience.

“We are thrilled to complete the acquisition of Endomag and are looking forward to working with our new colleagues to increase access to their innovative technologies, which complement and diversify our expanding interventional breast health portfolio,” said Erik Anderson, president of breast and skeletal health solutions at Hologic.

“With our shared commitment to advancing women’s health globally, we are excited to improve outcomes for patients and, together with our customers, redefine the standard of care for breast cancer intervention.”

Endomag’s product platform is the Sentimag localisation system, which uses a probe that works like a metal detector to detect Endomag’s magnetic seed and liquid tracer, for removing tumours and performing minimally invasive staging procedures.

The company’s technologies are used by thousands of of physicians across more than 45 countries.

Eric Mayes, chief executive officer of Endomag, added: “We are so proud of the company we built and the practice-changing breast surgery technologies that we developed following years of relentless research, innovation and deep engagement with clinicians.

“As we embark on this new journey with Hologic, I am filled with optimism about the opportunities for our team, our forthcoming innovations and our ability to impact even more women around the world.”